Noble Financial Lowers Earnings Estimates for GeoVax Labs

GeoVax Labs, Inc. (NASDAQ:GOVX) – Research analysts at Noble Financial lowered their Q2 2025 earnings per share (EPS) estimates for GeoVax Labs in a research report issued to clients and investors on Tuesday, April 15th. Noble Financial analyst R. Leboyer now anticipates that the company will earn ($0.44) per share for the quarter, down from their prior forecast of ($0.40). The consensus estimate for GeoVax Labs’ current full-year earnings is ($4.49) per share. Noble Financial also issued estimates for GeoVax Labs’ Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.54) EPS and FY2025 earnings at ($2.09) EPS.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.49. The business had revenue of $3.00 million for the quarter, compared to analyst estimates of $2.38 million.

A number of other equities analysts also recently commented on the stock. Alliance Global Partners reduced their target price on shares of GeoVax Labs from $15.00 to $8.50 and set a “buy” rating on the stock in a research note on Tuesday. D. Boral Capital reaffirmed a “buy” rating and set a $18.00 target price on shares of GeoVax Labs in a research note on Thursday, April 10th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of GeoVax Labs in a research note on Wednesday. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $12.90.

GeoVax Labs Stock Performance

NASDAQ GOVX opened at $0.83 on Thursday. GeoVax Labs has a fifty-two week low of $0.73 and a fifty-two week high of $11.18. The firm has a market capitalization of $11.48 million, a P/E ratio of -0.15 and a beta of 3.70. The stock’s fifty day moving average is $1.37 and its two-hundred day moving average is $1.95.

Institutional Investors Weigh In On GeoVax Labs

Hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new position in GeoVax Labs during the 3rd quarter worth approximately $97,000. Citadel Advisors LLC acquired a new position in GeoVax Labs in the fourth quarter valued at approximately $104,000. Northern Trust Corp purchased a new stake in shares of GeoVax Labs during the 4th quarter worth approximately $29,000. Finally, Geode Capital Management LLC raised its stake in GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after acquiring an additional 33,440 shares in the last quarter. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.